Psoriasis patients may get longer breaks between injections
NCT ID NCT07430319
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether people with psoriasis who are doing very well on the drug guselkumab (Tremfya) can safely wait longer than the usual 8 weeks between injections. Researchers will track 100 adults whose doctors have already extended their dosing intervals to see how their skin stays clear and how long they can keep up the longer schedule. The goal is to find a way to reduce treatment burden and healthcare costs without losing disease control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Nice
RECRUITINGNice, Alpes Maritimes, 06000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new daily pill quiet the immune attack behind psoriasis?
- Laser boost for stubborn psoriasis on hands and feet
- New oral pill HPP737 takes on psoriasis in Head-to-Head trial
- New oral pill HPP737 aims to clear psoriasis in phase 3 trial
- Psoriasis Patients' quality of life under the microscope
- Skin disease evolution under the microscope: a 17-Year look at what drives severity